Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 117Bevacizumab 102Oxaliplatin 99Capecitabine 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 68Magnetic Resonance Spectroscopy 65Fluorouracil 63Injections 62sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 50fludarabine 47Standard of Care 46Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43Biopsy 43venetoclax 42Leucovorin 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Rifaximin × Clear all
NCT06783153 2025-01-20

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Mansoura University

Phase 1/2 Not yet recruiting
80 enrolled
GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡